Efficacy and safety of apremilast in patients with mild-to-moderate psoriasis up to 32 weeks: Results from the extension phase of the randomized, phase 3 ADVANCE trial

Abstract

To the Editor: Mild-to-moderate psoriasis often involves special areas such as the scalp.1 Patients can experience substantial quality-of-life impairment despite limited overall skin involvement.1 In the phase 3 ADVANCE study (NCT03721172), apremilast demonstrated efficacy and tolerability in adults with mild-to-moderate psoriasis (static Physician's Global Assessment [sPGA] 2-3, psoriasis-involved body surface area [BSA] 2%-15%, and Psoriasis Area and Severity Index 2-15) inadequately controlled with/intolerant to ≥1 topical therapy.